HARBOURVEST-PARTNERS
HarbourVest Partners, a global, independent private markets asset manager with $76 billion in AUM, today announced the opening of its office in Frankfurt, Germany to address increased demand from institutional and private wealth clients for innovative and broad ranging investment solutions.
Frankfurt is the second international expansion for HarbourVest this year following the opening of its Singapore office in May. This grows the firm’s global footprint to 12 locations across EMEA, the Americas, and Asia Pacific. The office is fully integrated into the firm’s global network, providing clients with seamless access to private equity, private credit, real assets and infrastructure investments.
HarbourVest has been active in the German market for over 30 years, investing in the country and managing significant capital for investors such as pension funds, insurance companies, and family offices through fund and separately managed account solutions.
“We are pleased to announce the expansion of our European office network with the opening of our office in Frankfurt,” said Peter Wilson, Managing Director. “The German market is one of the strongest and most influential in Europe with institutional, private client, and wealth management channels continuously increasing their allocation to private markets and seeking innovative solutions from investment managers. This is an exciting stage in our evolution as we continue to grow our capabilities across EMEA and further deepen our connections with German clients.”
The Frankfurt team will be led by HarbourVest Managing Director Olav König, alongside newly appointed Principal Martina Schliemann, who brings 23 years of local market experience working with German managers and investors. The team will offer clients access to a broad range of expertise across investments, investor relations and operations.
The Frankfurt office will operate as HarbourVest Partners (Ireland) Limited, Zweigniederlassung Deutschland. HarbourVest Partners (Ireland) Limited, Zweigniederlassung Deutschland is authorized by the Central Bank of Ireland as a branch of HarbourVest Partners (Ireland) Limited, an Alternative Investment Fund Manager authorized to conduct certain regulated activities within the EU. HarbourVest’s operations in Germany will be supervised by the Board of Directors of HarbourVest Partners (Ireland) Limited.
The firm has also become a proud member of the Bundesverband Alternative Investments e.V. (BAI), the industry body for alternative investments in Germany.
For more information about HarbourVest, please visit https://www.harbourvest.com/ .
ABOUT HARBOURVEST
HarbourVest is an independent, global private markets investment specialist with over 35 years of experience and more than $76 billion in assets under management, as of March 31, 2021. The Firm’s powerful global platform offers clients investment opportunities in private equity, private credit and real assets and infrastructure through primary fund investments, secondary investments, and direct co-investments, in commingled funds or separately managed accounts. HarbourVest has more than 700 employees, including more than 150 investment professionals across Asia, Europe, and the Americas. This global team has committed more than $46 billion to newly-formed funds, completed over $29 billion in secondary purchases, and invested over $21 billion directly in operating companies. Partnering with HarbourVest, clients have access to customized solutions, longstanding relationships, and actionable insights.
Nothing herein should be construed as a solicitation, offer, recommendation, representation of suitability, legal advice, tax advice, or endorsement of any security or investment and should not be relied upon by you in evaluating the merits of investing in HarbourVest funds or in any other investment decision. Information about the fund is not representative of any other HarbourVest fund or investment product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release
Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r
Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset
Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom